Trial intelligence / Profile preview

Phase 1 first-in-human study of RG2459 alone and with simeprevir in healthy volunteers and patients with chronic hepatitis C

NL-OMON41383Phase 1Active, not recruiting

Sponsor

Regulus Therapeutics

Start

Feb 2014

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1